Madopar Quick (Benserazide, Levodopa)

Levodopa/Benserazide, the active ingredients in Madopar Quick, are antiparkinson agents presented as tablets for oral use. They treat Parkinson's disease by restoring dopamine activity in the brains of affected patients, helping to improve motor function and reduce symptoms such as rigidity and bradykinesia.

GNH USA supplies Madopar Quick as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar Quick is used in the management of Parkinson's disease and related motor disorders.

- Parkinson's disease: improves motor control, reduces rigidity, tremor, and bradykinesia. - Early-stage Parkinson's disease: helps initiate symptomatic therapy when dopamine deficiency begins. - Advanced Parkinson's disease with motor fluctuations: reduces "off" periods and enhances overall daily functioning.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Orthostatic hypotension: dizziness upon standing. - Dyskinesia: involuntary movements, especially at higher doses. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Severe psychiatric disturbances: hallucinations, confusion, or depression requiring immediate medical attention.

Patients should be monitored for cardiovascular and psychiatric effects, especially when initiating therapy.

- Dose titration: start low and increase gradually to minimize side effects. - Concomitant MAO‑B inhibitors: avoid unless specifically prescribed, due to risk of hypertensive crisis. - Renal or hepatic impairment: adjust dose based on clinical response. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Elderly patients: monitor for falls and confusion. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Madopar Quick may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: can cause hypertensive emergencies. - Antipsychotics with strong dopamine blockade: may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance orthostatic hypotension. - Iron or vitamin B6 supplements: can decrease levodopa absorption; separate dosing by at least 2 hours. - SSRIs and SNRIs: may increase risk of serotonin syndrome when combined with MAO‑B inhibitors.